Research Topics
Species | Mikkael SekeresSummaryAffiliation: Cleveland Clinic Foundation Country: USA Publications
| Collaborators
|
Detail Information
Publications
The challenge of acute myeloid leukemia in older patientsMikkael A Sekeres
Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Curr Opin Oncol 14:24-30. 2002..Future directions include therapies targeted at immunomodulation, at angiogenesis, and in particular against intracellular signals that promote proliferation at the expense of differentiation...- New data with arsenic trioxide in leukemias and myelodysplastic syndromesMikkael A Sekeres
Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Clin Lymphoma Myeloma 8:S7-S12. 2007.... 
Improving the diagnosis and treatment of patients with myelodysplastic syndromes through a performance improvement initiativeMikkael A Sekeres
Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
Leuk Res 37:422-6. 2013..Improvements related to patient communication and disease education were also observed and support the overall efficacy and value of PI in MDS patient care...
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres
Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Cleveland, OH 44195, USA
Blood 120:4945-51. 2012..TET2/DNMT3A/IDH1/2 mutational status was associated with response in a limited number of patients. The lenalidomide/azacitidine combination is well-tolerated and highly active in treating greater-risk MDS...- Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemiaMikkael A Sekeres
Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
Haematologica 98:119-28. 2013.... - Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomideYuka Sugimoto
Department of Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
J Hematol Oncol 5:4. 2012..We hypothesized that improved detection of chromosomal abnormalities with new karyotyping tools may better predict response to LEN... - How to manage lower-risk myelodysplastic syndromesM A Sekeres
Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
Leukemia 26:390-4. 2012..Newer therapies hold the promise of activity in patients who have failed standard regimens... - Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromesMikkael A Sekeres
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
Cancer 117:992-1000. 2011..Romiplostim is a peptibody protein that augments thrombopoiesis by activating the thrombopoietin receptor... - The avastin storyMikkael A Sekeres
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
N Engl J Med 365:1454-5. 2011..But neither article covered a basic, patient-focused theme that we, the oncologists on the panel, considered: that of giving hope - but not false hope. Avastin received accelerated approval from . . ... - Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromesMikkael A Sekeres
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
J Clin Oncol 26:5943-9. 2008..Lenalidomide-induced cytopenias occurring early in treatment may serve as a surrogate marker of clonal suppression and, therefore, may be predictive of a TI response... - Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based surveyMikkael A Sekeres
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Desk R35, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
Oncologist 16:904-11. 2011..S. Little information is available regarding how aware MDS patients are of their disease severity, prognosis, and treatment outcomes... - A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemiaMikkael A Sekeres
Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
Cancer 117:1253-61. 2011..AML therapies thus may have activity in MDS. In the current study, phase 2 study data of arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in CD33-positive patients with MDS and secondary AML (sAML) were presented... - Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveysMikkael A Sekeres
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
J Natl Cancer Inst 100:1542-51. 2008..We describe these characteristics in a large group of recently diagnosed and existing (ie, established) MDS patients... - Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010Mikkael A Sekeres
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Ohio 44195, USA
J Natl Compr Canc Netw 9:57-63. 2011..Erythropoiesis stimulating agents are used by more than 50% of patients, although the use of disease-modifying agents is increasing, and may ultimately have an impact on the number of patients living with MDS... - Are we nearer to curing patients with MDS?Mikkael A Sekeres
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, OH 44195, USA
Best Pract Res Clin Haematol 23:481-7. 2010..Treatment options range from supportive care, to disease-modifying chemotherapeutic agents, to stem cell transplantation, to therapies that may affect quality of life, improve survival, or even cure the disease... - Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres
Department of Hematologic Oncology and Blood Disorders, Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
Am J Hematol 86:102-3. 2011..We conclude that the addition of lenalidomide to azacitidine provides additional clinical benefit over azacitidine monotherapy... - Arsenic trioxide as a treatment for myelodysplastic syndromeMikkael A Sekeres
Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Curr Hematol Rep 4:59-63. 2005..MDS patients whose cells express the EVI1 mutation in particular may derive benefit from this therapy... - The myelodysplastic syndromesMikkael A Sekeres
Cleveland Clinic Lerner College of Medicine, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA
Expert Opin Biol Ther 7:369-77. 2007..Agents such as thalidomide, lenalidomide and the hypomethylating drugs 5-azacytidine and decitabine have shown promising efficacy and tolerability in clinical trials, and may represent a springboard for future treatment combinations... - The impact of a physician awareness group and the first year of training on hematology-oncology fellowsMikkael A Sekeres
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
J Clin Oncol 21:3676-82. 2003..To assess the impact of a Balint-like physician awareness group on hematology-oncology fellows' attitudes and measure changes in attitudes during the first fellowship year... - Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndromeM A Sekeres
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Leukemia 18:809-16. 2004..Regardless of treatment choice, patients report not being offered treatment options and overestimate their chances of cure. In IC patients, QOL decreases during hospitalization but rebounds after discharge... - Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemiaMikkael A Sekeres
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
Blood 103:4036-42. 2004..African Americans and whites with AML differ with respect to important prognostic factors. African American men have worse CR rates and overall survival than whites and African American women, and should be considered a poor-risk group... - Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres
Myelodsyplastic Syndromes Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
J Clin Oncol 28:2253-8. 2010..These agents may complement each other by targeting both the bone marrow microenvironment and hypomethylating action on the malignant clone... - Arsenic trioxide as a treatment for myelodysplastic syndromeMikkael A Sekeres
Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Curr Hematol Malig Rep 1:34-8. 2006..MDS patients whose cells express the EVI1 mutation in particular may derive benefit from this therapy... - Alternative treatments for myelodysplastic syndromesMikkael Sekeres
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Semin Hematol 42:S32-7. 2005..Herein, we summarize an array of novel treatments in development for the management of MDS... - A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605Mikkael A Sekeres
Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
Blood 118:523-8. 2011..In conclusion, lenalidomide as a single agent has modest activity in older del(5q) AML patients. Southwest Oncology Group Study S0605 is registered at www.clinicaltrials.gov as NCT00352365... - Non-transplant therapy for older adults with acute myeloid leukemiaMikkael A Sekeres
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
J Natl Compr Canc Netw 4:51-6. 2006..Clinical trials should be considered at every stage of treatment in this group of patients... - Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollmentMikkael A Sekeres
Myelodysplastic Syndromes Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
Blood 114:2575-80. 2009..quot; This article considers some of these issues as they relate to study design, including how to identify certain MDS populations and define disease progression... - Immunomodulation in myelodysplastic syndromesMikkael A Sekeres
Cleveland Clinic Lerner College of Medicine, Department of Hematologic Malignancies and Blood Disorders, Taussig Cancer Center, Cleveland Clinic Foundation, Desk R35, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
Best Pract Res Clin Haematol 19:757-67. 2006..Agents such as thalidomide, lenalidomide, and infliximab have shown promising efficacy and tolerability in clinical trials, and may represent a springboard for future treatment combinations... - A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromesMikkael A Sekeres
Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA
Cancer 109:1125-32. 2007..For low-risk MDS the optimal initial therapy (GF vs nongrowth factor [NGF] therapies, including differentiation and immunomodulatory agents) based on response rates to NGF and GF and survival, has not been defined... - Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patientsMikkael A Sekeres
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Blood 113:28-36. 2009..AML therapy should be initiated immediately in younger patients. Delaying treatment does not seem harmful in older patients, allowing individualized approaches... - Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemiaMatt Kalaycio
Department of Hematologic Malignancies and Blood Disorders, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio 44195, USA
Am J Hematol 83:831-4. 2008..Our intensive and risk-adapted, stem cell transplant approach to the treatment of patients with AML requires a better definition of risk and does not appear to substantially improve results compared with more standard approaches... - Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patientsAnjali S Advani
Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH, USA
BMC Cancer 10:387. 2010.... - Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)Anjali S Advani
Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH 44195, USA
Br J Haematol 153:504-7. 2011..These data provide a rationale for the use of histone deacetylase inhibitors in the treatment of relapsed ALL... - Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemiaAnjali S Advani
Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH 44195, USA
Leuk Lymphoma 49:1560-6. 2008..27, CI (1.04-1.55), p = 0.019] and decreased overall survival [HR 1.34, CI (1.08-1.67), p = 0.009]. Delayed time from IC to PRT (> or =6.6 weeks) was associated with a statistically worse progression-free and overall survival... - A prognostic scoring system for adult patients less than 60 years of age with acute lymphoblastic leukemia in first relapseAnjali Advani
Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH 44195, USA
Leuk Lymphoma 50:1126-31. 2009..Patients with a prognostic score of greater than 1 have a poor prognosis, even with BMT, and should be considered for treatment with innovative approaches such as Phase 1 clinical trials... - Aberrant DNA methylation is a dominant mechanism in MDS progression to AMLYing Jiang
Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, OH 44195, USA
Blood 113:1315-25. 2009..However, the ubiquity, extent, and correlation with disease progression suggest that aberrant DNA methylation is the dominant mechanism for TSG silencing and clonal variation in MDS evolution to AML... - p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignanciesYogen Saunthararajah
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Semin Oncol 39:97-108. 2012..Decitabine or 5-azacytidine dose and schedule can be rationalized to emphasize this mechanism of action, as an alternative or complement to conventional apoptosis-based oncotherapy... - Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AMLAnjali S Advani
Taussig Cancer Center, Leukemia Program, The Cleveland Clinic CCF, Cleveland, OH 44195, USA
Leuk Res 32:913-8. 2008..Whether inhibiting c-kit in patients with AML will alter prognosis is the basis of ongoing clinical trials... - The role of post-remission chemotherapy for older patients with acute myelogenous leukemiaRony M Abou-Jawde
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Leuk Lymphoma 47:689-95. 2006..21 and P = 0.15, respectively). PRT has not clearly improved survival in older patients with AML, and therefore the routine addition of chemotherapy to older patients in complete remission is not indicated... - Development of a modified surveillance definition of central line-associated bloodstream infections for patients with hematologic malignanciesMegan J Digiorgio
Department of Infection Prevention, Quality and Patient Safety Institute, Cleveland, Ohio, USA
Infect Control Hosp Epidemiol 33:865-8. 2012..To develop a modified surveillance definition of central line-associated bloodstream infection (mCLABSI) specific for our population of patients with hematologic malignancies to better support ongoing improvement efforts at our hospital... - OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemiaAnjali S Advani
Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
Leuk Lymphoma 51:606-12. 2010..10, p = 0.036) and a trend toward a worse OS (HR 1.10, p = 0.063). OCT-2 may act as a cell survival factor in AML by mediating expression of downstream targets, such as BCL-2. These results will need to be validated prospectively... - A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemiaAnjali S Advani
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA
Leuk Res 34:1622-6. 2010..The maximum tolerated dose of IM was 300 mg. The dose-limiting toxicity was Grade 3-4 hepatic toxicity. The CR/CRp rate was 57%. Cytotoxic therapy that includes IM for relapsed AML is well-tolerated and effective... - Myelodysplastic syndromes: a practical approach to diagnosis and treatmentAfsaneh Barzi
Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Cleve Clin J Med 77:37-44. 2010..MDS are now considered the most common form of leukemia, and in some cases deserve immediate intervention. This review describes common presentations of MDS, optimal diagnostic approaches, and therapies for lower-and higher-risk disease... - High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromesRamon Tiu
Experimental Hematology and Hematopoiesis Section, Cleveland Clinic, Cleveland, Ohio 44195, USA
Exp Hematol 35:240-51. 2007..Therefore, it is likely that chromosomal defects in myelodysplastic syndromes may be more frequent than predicted by metaphase cytogenetics and new cryptic lesions may be revealed by precise analysis methods... - Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemiaRachid Baz
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
Cancer 110:1752-9. 2007..Earlier clinical trials have yielded conflicting results and possibly a minor survival benefit, often offset by a longer hospitalization time... - Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemiaNelli Bejanyan
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
Cancer 116:3614-20. 2010..The authors investigated quality of care and clinical outcomes of newly diagnosed acute myeloid leukemia (AML) patients who were hospitalized on weekends versus weekdays and treated with induction chemotherapy... - The epidemiology of myelodysplastic syndromesMikkael A Sekeres
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Hematol Oncol Clin North Am 24:287-94. 2010..The most common risk factors for developing MDS include advanced age, male gender, previous exposure to chemotherapy or radiation therapy, smoking, or, in rare cases, exposure to industrial chemicals... - Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemiaJennifer K Long
Department of Pharmacy, Clinical Microbiology Section, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Mayo Clin Proc 80:1215-6. 2005..No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives... - Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromesAli Reza Golshayan
Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
Br J Haematol 137:125-32. 2007..Decision tools need to be developed to determine which therapy to choose for patients with low-risk MDS... - Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromesLukasz P Gondek
Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
Exp Hematol 35:1728-38. 2007..We hypothesize that more precise methods of chromosomal analysis will detect new/additional cryptic lesions in a higher proportion of MDS patients... - Myelodysplastic syndromes: more prevalent than we knowSatinderpal K Sandhu
Case Western Reserve University School of Medicine, and Senior Health and Wellness Center, MetroHealth Medical Center, Cleveland, Ohio, USA
Geriatrics 63:10-7. 2008..Comorbidities and functional issues make this disease challenging to diagnose and treat in geriatric patients. This article reviews the epidemiology, classification, and treatment options for MDS... - Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicinHien K Duong
Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio 44195, USA
Clin Interv Aging 4:197-205. 2009..In this population, GO has an acceptable toxicity and yields response rates approaching 30%. The efficacy of GO as monotherapy and in combination therapy for treatment of both de novo and relapsed AML continues to be investigated... - FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q)Hideki Makishima
Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA
Leuk Res 34:447-53. 2010.... - New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemiaRamon V Tiu
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
J Clin Oncol 27:5219-26. 2009..We hypothesized that SNP-A will improve detection of chromosomal defects in AML and that this would enhance the prognostic value of MC... - The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromesRamon V Tiu
Cleveland Clinic Taussig Cancer Center, Department of Hematologic Oncology and Blood Disorders, 9500 Euclid Avenue R35, Cleveland, Ohio 44195, USA
Expert Opin Biol Ther 8:1021-30. 2008.... - Thalidomide use and digital gangreneTyler Y Kang
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
J Clin Oncol 24:5328. 2006 - Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AMLLukasz P Gondek
Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, OH, USA
Blood 111:1534-42. 2008..SNP-A-based karyotyping shows superior resolution for chromosomal defects, including UPD. This technique further complements MC to improve clinical prognosis and targeted therapies... - Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemiaCristina P Rodriguez
Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Avenue R35, Cleveland, OH 44195, USA
Leuk Res 32:413-20. 2008..While socioeconomic status (SES) and the distance patients travel to a treatment center (DTC) impact survival of certain solid tumors, little is known of their influence in acute myeloid leukemia (AML)... - Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignanciesHideki Makishima
Taussig Cancer Institute R40, 9500 Euclid Ave, Cleveland OH 44195, USA
J Clin Oncol 27:6109-16. 2009..We examined the role and frequency of Cbl gene family mutations in MPN and related conditions... - 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignanciesAndrew J Dunbar
Department of Hematologic Oncology and Blood Disorders, Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA
Cancer Res 68:10349-57. 2008..Acquired mutations of c-Cbl E3 ubiquitin ligase may explain the pathogenesis of a clonal process in a subset of MDS/MPD, including CMML... - Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblastsZachary P Nearman
Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland, Ohio, USA
Am J Hematol 82:1076-9. 2007.... - Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutationsHadrian Szpurka
Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
Leuk Res 34:969-73. 2010..JAK2V617F/MPLW515L mutations were absent in TET2/ASXL1 mutants, indicating that similar clinical phenotype can be produced by various MPN-associated mutations and that additional unifying lesions may be present in RARS-T... - Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unitSnehal G Thakkar
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
Cancer 112:2233-40. 2008..Predictors of outcome and rates of successful discharge have not been defined for patients with acute leukemia admitted to intensive care units (ICUs) in the US... - Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?Mikkael A Sekeres
H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
Curr Hematol Rep 4:182-5. 2005.... - Older adults with acute myeloid leukemiaMikkael A Sekeres
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Curr Oncol Rep 4:403-9. 2002..Herein we characterize the intrinsic biologic features of AML as it occurs in the older population, review currently available therapeutic approaches, and discuss therapeutic strategies in development... - White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemiaHyo Sook Han
Division of Hematology and Oncology, Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
Leuk Lymphoma 48:1561-8. 2007..12 x 10(9)/l HR 1.5, 95%CI 0.96 - 2.37, p = 0.08), as predictors of worse outcomes. Time to WBC nadir predicts survival. The absolute WBC nadir value follows a J-curve, with lower value indicating a worse outcome... - The incidence and impact of thrombocytopenia in myelodysplastic syndromesHagop Kantarjian
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 109:1705-14. 2007..Many approved and investigational MDS therapies caused or exacerbated preexisting thrombocytopenia. The incidence of severe bleeding in MDS was greater than reported in current guidelines...